IRCT2015052322381N1 IRCT 2016-09-17 Neyshabour University of Medical Sciences Evaluation of effect of Curcumin on the serum levels of 12-inflammatory cytokines & highly sensitive C-reactive protein Evaluation of effect of Curcumin on the serum levels of 12-inflammatory cytokines and highly sensitive C-reactive protein level in the patients with Non-alcoholic fatty liver disease (A double-blind, randomized, placebo-controlled trial) 2016-08-22 anticipated 43 Complete https://irct.ir/trial/19311 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Two letters were prepared and written on two sheets “A” for “curcumin” and “B” for “control.” AABB, ABAB, ABBA, BBAA, BABA, BAAB, all quad blocks were possible. Then the number was selected randomly via a table of random numbers, Blinding description: To ensuring that implementation of the random allocation sequence occurs without the knowledge of which patient will receive which treatment, the entire randomization process was concealed. For this purpose, the drugs were already put in envelopes labeled a serial number from 1 to 80. No one knew the nature of the envelopes except the coordinator of the trial. 3 NAFLD. Intervention 1: Curcumin Phytosome (Meriva) with dose 250 mg/day (phospholipidated curcumin, 250 mg equivalent to 50 mg curcumin). Intervention 2: Curcumin C3 complexTM (500 mg) plus BioperineTM (5 mg, patented extract obtained from black pepper fruits (Piper nigrum) standardized minimum to 95% Piperine. Intervention 3: Control group or Placebo consumes capsules lactose with similar shape and size of intervention groups and a dose of 250 mg/day. Drug consumption is as oral during a 2-month period. No - There is not a plan to make this available Justification or reason for not sharing IPD is If the request is made by a researcher, the data will be shared according to the relevant criteria.